



US009409951B2

(12) **United States Patent**
Lattuada et al.

(10) **Patent No.:** US 9,409,951 B2
(45) **Date of Patent:** *Aug. 9, 2016

(54) **INTEGRIN TARGETED SYNTHETIC LIGANDS FOR DIAGNOSTIC AND THERAPEUTIC APPLICATIONS**

7,897,142 B2 3/2011 Cuthbertson et al.
8,636,977 B2 1/2014 Lattuada et al.
2008/0317668 A1 12/2008 Lattuada et al.

(71) Applicant: **BRACCO IMAGING S.P.A.**, Milan (IT)

FOREIGN PATENT DOCUMENTS

(72) Inventors: **Luciano Lattuada**, Colleferro Giacosa (IT); **Pierfrancesco Morosini**, Villanova del Sillaro (IT); **Fulvio Uggeri**, Colleferro Giacosa (IT); **Silvio Aime**, Carignano (IT); **Enzo Terreno**, Bibiana (IT); **Daniela Delli Castelli**, Bibiana (IT); **Carlo Scolastico**, Lerici (IT); **Leonardo Manzoni**, Milan (IT); **Daniela Arosio**, Milan (IT)

EP	1181940 A2	2/2002
EP	0 927 045 B1	12/2005
WO	98/01795 A2	3/1998
WO	2004/011487 A2	2/2004
WO	2005/007654	1/2005
WO	2005/042531	5/2005
WO	2006/092722	9/2006
WO	2008/102233 A1	8/2008
WO	2010/046900 A2	4/2010
WO	2010/076334 A2	7/2010
WO	2012/062777 A1	5/2012

(73) Assignee: **BRACCO IMAGING S.P.A.**, Milan (IT)

OTHER PUBLICATIONS

(*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 337 days.

Artale et al. "Synthesis of substituted conformationally constrained 6,5- and 7,5-fused bicyclic lactams as dipeptide mimics" *Tetrahedron* 59:6241-6250 (Aug. 2003).

This patent is subject to a terminal disclaimer.

Belvisi et al. "Targeting integrins: Insights into structure and activity of cyclic RGD pentapeptide mimics containing azabicycloalkane amino acids" *Bioorganic Med. Chem.* 14:169-180 (Jan. 2006).

(21) Appl. No.: 14/153,706

Belvisi et al. "Potent integrin antagonists from a small library of RGD-including cyclic pseudopeptides" *Organic Lett.* 3:1001-1004 (Apr. 2001).

(22) Filed: Jan. 13, 2014

Belvisi et al. "Cyclic RGD peptides containing azabicycloalkane reverse-turn mimics" *Helv. Chim. Acta* 85:4353-4368 (Dec. 2002).

(65) **Prior Publication Data**

Breeman et al. "Optimising conditions for radiolabelling of DOTA-peptides with ⁹⁰Y, ¹¹¹In and ¹⁷⁷Lu at high specific activities" *Eur. J. Nucl. Med. Mol.* 30:917-920 (Jun. 2003).

US 2014/0178302 A1 Jun. 26, 2014

Brugieres et al. "Randomised double blind trial of the safety and efficacy of two gadolinium complexes (Gd-DTPA and Gd-DOTA)" *Neuroradiology* 36:27-30 (1994).

Related U.S. Application Data

Chen et al. "Pegylated Arg-Gly-Asp peptide: ⁶⁴Cu labeling and PET imaging of brain tumor $\alpha_1\beta_3$ -integrin expression" *J. Nucl. Med.* 45:1776-1783 (Oct. 2004).

(63) Continuation of application No. 11/885,353, filed as application No. PCT/IB2006/000455 on Mar. 3, 2006, now Pat. No. 8,636,977.

Chen et al. "MicroPET and autoradiographic imaging of breast cancer α_v -integrin expression using ¹⁸F- and ⁶⁴Cu-labeled RGD peptide" *Bioconjug. Chem.* 15:41-49 (Jan.-Feb. 2004).

(30) **Foreign Application Priority Data**

Colombo et al. "Conformationally constrained dipeptides: Synthesis of bicyclic lactams by stereoselective radical cyclizations" *Gazzetta Chim. Ital.* 126:543-554 (Jan. 1996).

Mar. 3, 2005 (IT) MI2005A0328

Feng & Lubell "Synthesis of enantiopure 7-[3-azidopropyl]indolizidin-2-one amino acid. A constrained mimic of the peptide backbone geometry and heteroatomic side-chain functionality of the Ala-Lys dipeptide" *J. Org. Chem.* 66:1181-1185 (Jan. 2001).

(51) **Int. Cl.**

Haubner et al. "Stereoisomeric peptide libraries and peptidomimetics for designing selective inhibitors of the $\alpha_1\beta_3$ integrin for a new cancer therapy" *Angew. Chem. Int. Ed.* 36:1375-1389 (Aug. 1997).

C07K 7/64 (2006.01)
C07K 5/078 (2006.01)
C07D 401/06 (2006.01)
C07D 471/04 (2006.01)

(Continued)

(52) **U.S. Cl.**

CPC **C07K 7/64** (2013.01); **C07D 401/06** (2013.01); **C07D 471/04** (2013.01); **C07K 5/06139** (2013.01)

(58) **Field of Classification Search**

Primary Examiner — Michael G Hartley

None

Assistant Examiner — Jennifer Lamberski

See application file for complete search history.

(74) Attorney, Agent, or Firm — Vivifar Law, PLLC

(56) **References Cited**

ABSTRACT

U.S. PATENT DOCUMENTS

The present invention relates to a novel class of diagnostically or therapeutically effective compounds comprising novel aza-bicycloalkane based cyclic peptides, acting as a targeting moiety towards integrin receptors.

5,268,486 A 12/1993 Waggoner et al.
6,083,485 A 7/2000 Licha et al.
6,261,537 B1 7/2001 Klaveness et al.
7,371,364 B2 5/2008 Li et al.
7,655,217 B2 2/2010 Licha et al.